Metabolic Profiling of Obesity With and Without the Metabolic Syndrome: A Multisample Evaluation.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
19 04 2022
Historique:
received: 21 09 2021
pubmed: 6 1 2022
medline: 21 4 2022
entrez: 5 1 2022
Statut: ppublish

Résumé

There is a dispute whether obesity without major metabolic derangements may represent a benign condition or not. We aimed to compare the plasma metabolome in obese subjects without metabolic syndrome (MetS) with normal-weight subjects without MetS and with obese subjects with MetS. This was a cross-sectional study at 2 academic centers in Sweden. Individuals from 3 population-based samples (EpiHealth, n = 2342, SCAPIS-Uppsala, n = 4985, and SCAPIS-Malmö, n = 3978) were divided into groups according to their body mass index (BMI) and presence/absence of MetS (National Cholesterol Education Program [NCEP]/consensus criteria). In total, 791 annotated endogenous metabolites were measured by ultra-performance liquid chromatography-tandem mass spectrometry. We observed major differences in metabolite profiles (427 metabolites) between obese (BMI ≥ 30 kg/m2) and normal-weight (BMI < 25 kg/m2) subjects without MetS after adjustment for major lifestyle factors. Pathway enrichment analysis highlighted branch-chained and aromatic amino acid synthesis/metabolism, aminoacyl-tRNA biosynthesis, and sphingolipid metabolism. The same pathways, and similar metabolites, were also highlighted when obese subjects with and without MetS were compared despite adjustment for BMI and waist circumference, or when the metabolites were related to BMI and number of MetS components in a continuous fashion. Similar metabolites and pathways were also related to insulin sensitivity (Matsuda index) in a separate study (POEM, n = 501). Our data suggest a graded derangement of the circulating metabolite profile from lean to obese to MetS, in particular for metabolites involved in amino acid synthesis/metabolism and sphingolipid metabolism. Insulin resistance is a plausible mediator of this gradual metabolic deterioration.

Identifiants

pubmed: 34984454
pii: 6497401
doi: 10.1210/clinem/dgab922
doi:

Substances chimiques

Sphingolipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1337-1345

Subventions

Organisme : Swedish Heart-Lung Foundation
ID : 2019-0526
Organisme : Swedish Research Council
ID : 2017-02554
Organisme : European Research Council
ID : ERC-STG-2015-679242
Pays : International
Organisme : Skåne University Hospital
Organisme : Swedish National Health Service
Organisme : Swedish Foundation for Strategic Research

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Lars Lind (L)

Department of Medical Sciences, Uppsala University, Sweden.

Samira Salihovic (S)

Inflammatory Response and Infection Susceptibility Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.

Johan Sundström (J)

Department of Medical Sciences, Uppsala University, Sweden.

Sölve Elmståhl (S)

Department of Clinical Sciences, Division of Geriatric Medicine, Lund University, Malmö University Hospital, Malmö, Sweden.

Ulf Hammar (U)

Department of Medical Sciences, Uppsala University, Sweden.

Koen Dekkers (K)

Department of Medical Sciences, Uppsala University, Sweden.

Johan Ärnlöv (J)

Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden.
School of Health and Social Studies, Dalarna University, Falun, Sweden.

J Gustav Smith (JG)

Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital , Lund, Sweden.
The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund University, Lund, Sweden.

Gunnar Engström (G)

Department of Clinical Sciences, Lund University, Malmö, Sweden.

Tove Fall (T)

Department of Medical Sciences, Uppsala University, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH